Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer, hematological cancer, and pancreatic cancer.

Abstract: A glass syringe barrel is provided that has an at least partially conically shaped upper portion and a longitudinal axis. The glass syringe barrel has a top end through which a liquid can be ejected and a bottom end into which a plunger stopper can be pushed. The glass syringe barrel includes, in a direction from the top end to the bottom end, a cone, a shoulder region, and a body region. The shoulder region has and outer contour that has a concave and substantially circular arc-shaped area c1 with an outer radius r1. The outer contour of the glass syringe barrel in the shoulder region is defined by a certain minimum value the radius of curvature.

Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.

Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

Abstract: A barrier film, a document including a barrier coating, and a method for producing a document are described. A document includes a substrate, printed data on a surface of the substrate, and a barrier coating. The barrier coating is disposed between a portion of the printed data and a portion of an adhesive. The portion of the adhesive is disposed between a portion of a protective layer and a portion of the substrate.

Abstract: Systems and methods wherein one or more processing operations on an identification document occur after a radiation curable material is applied to a surface of the identification document but before the radiation curable material is fully cured. The one or more processing operations can occur before any curing of the radiation curable material takes place. Alternatively, the one or more processing operations can occur after the radiation curable material has been partially cured, and before the radiation curable material is fully or completely cured.

Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.

Abstract: A barrier film, a document including a barrier coating, and a method for producing a document are described. A document includes a substrate, printed data on a surface of the substrate, and a barrier coating. The barrier coating is disposed between a portion of the printed data and a portion of an adhesive. The portion of the adhesive is disposed between a portion of a protective layer and a portion of the substrate.

Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.

Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.

Abstract: The present invention relates to a combination of cell lines as well as a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor anti-tumor agent. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell or collection of cells or cell lines to treatment with a drug such as an HSP90 inhibitor anti-tumor agent is described herein.

Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and.

Abstract: A system and method are provided for correcting a hang condition caused by an unanticipated exception during a printing process. The method may include providing a set of predetermined rules according to which the print process modules interact to control the printing process. The method further may include monitoring, from a self-correcting module, a state of each of a plurality of the print process modules. The method may also include determining that the printing device is hung during a printing process, based on at least one predetermined rule and the state of at least one print process module, and setting the state of at least one print process module to a default condition.